Novel markers of inflammation in atherosclerosis

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 164-170

  Virani, Salim S ^b   Polsani, Venkateshwar R ^b   Nambi, Vijay ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; ROSUVASTATIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE MARKER; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; PREDICTION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PEROXIDASE; RISK ASSESSMENT; ROC CURVE;

EID: 41749084175     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0024-0     Document Type: Review

References (59)

1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2002.
2. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
4. Kannel WB: The Framingham heart study. Ann Intern Med 1961, 55:33-50.
5. Virani SS, Ballantyne CM: How to identify patients with vulnerable plaques. Diabetes Obes Metab 2007 [Epub ahead of print].
6. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
7. Roy D, Quiles J, Avanzas P, et al.: A comparative study of markers of inflammation for the assessment of cardiovascular risk in patients presenting to the emergency department with acute chest pain suggestive of acute coronary syndrome. Int J Cardiol 2006, 109:317-321.
8. Upadhya B, Applegate RJ, Sane DC, et al.: Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. Am J Cardiol 2005, 96:515-518.
9. Verma S, Szmitko P: Is C-reactive protein a culprit in atherogenesis? In C-Reactive Protein and Cardiovascular Disease. Edited by Ridker PM, Rifai N. St-Laurent, Quebec: MediEdition; 2006:53-62.
10. Campbell P, Blake GJ: C-reactive protein and hypertension. In C-Reactive Protein and Cardiovascular Disease. Edited by Ridker PM, Rifai N. St-Laurent, Quebec: MediEdition; 2006:141-152.
11. Ridker PM, Cushman M, Stamper MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
12. Ridker PM, Buring JE, Shih J, et al.: Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
13. Pradhan AD, Manson JE, Rossouw JE, et al.: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002, 288:980-987.
14. Pai JK, Pischon T, Ma J, et al.: Inflammatory markers, and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
15. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
16. Miller M, Zhan M, Havas S: High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005, 165:2063-2068.
17. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
18. Ridker PM, Morrow DA, Rose LM, et al.:Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/d1 and C-reactive protein <2 mg/1: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45:1644-1648.
19. Ridker PM; JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.
20. Ballantyne CM, Nambi V: Markers of inflammation and their clinical significance. Atheroscler Suppl 2005, 6:21-29.
21. Virani SS, Nambi V: The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis. Curr Atheroscler Rep 2007, 9:97-103.
22. Caslake MJ, Packard CJ, Suckling KE, et al.: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000, 150:413-419.
23. Kolodgie FD, Burke AP, Skorija KS, et al.: Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006, 26:2523-2529.
24. Packard CJ, O'Reilly DS, Caslake MJ, et al.: Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
25. Blake GJ, Dada N, Fox JC, et al.:A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001, 38:1302-1306.
26. Ballantyne CM, Hoogeveen R, Bang H et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
27. Ballantyne CM, Hoogeveen RC, Bang H, et al.: Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005, 165:2479-2484.
28. Oei H-HS, van der Meer IM, Hofman A, et al.: Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 2005, 111:570-575.
29. Brilakis ES, McConnell JP, Lennon RJ, et al.: Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005, 26:137-144.
30. O'Donoghue M, Morrow DA, Sabatine MS, et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
31. Hoogeveen RC, Ballantyne CM: PLAC™ test for identification of individuals at increased risk for coronary heart disease. Expert Rev Mol Diagn 2005, 5:9-14.
32. Davison MH, Stein EA, Bays HE, et al.: Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007, 29:1354-1367.
33. Nambi V: The use of myeloperoxidase as a risk marker for atherosclerosis. Curr Atheroscler Rep 2005, 7:127-131.
34. Sugiyama S, Okada Y, Sukhova GK, et al.: Macrophage myeloperoxiodase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001, 158:879-891.
35. Zhang R, Brennan ML, Fu X, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001, 286:2136-2142.
36. Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595-1604.
37. Baldus S, Heeschen C, Meinertz T, et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1140-1445.
38. Meuwese MC, Stroes ES, Hazen SL, et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population study. J Am Coll Cardiol 2007, 50:159-165.
39. Anuurad E, Boffa MB, Koschinsky ML, Berglund L: Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006, 26:751-772.
40. Marcovina SM, Koschinsky ML: Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998, 82:57U-66U.
41. Rosengren A, Wilhelmsen L, Eriksson E, et al.: Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990, 301:1248-1251.
42. Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997, 17:239-245.
43. Sigurdsson G, Baldursdottir A, Sigvaldason H, et al.: Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992, 69:1251-1254.
44. Schaefer EJ, Lamon-Fava S, Jenner JL, et al.: Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994, 271:999-1003.
45. Alfthan G, Pekkanen J, Jauhiainen M, et al.: Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994, 106:9-19.
46. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993, 270:2195-2199.
47. Knopp RH, Alagona P, Davidson M, et al.: Efficacy of a time-release form of niacin (Niaspan) given once-a-night Equivalent versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097-1104.
48. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al.: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001, 85:619-625.
49. Ray KK, Morrow DA, Sabatine MS, et al.: Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007, 115:3071-3078.
50. Jousilahti P, Salooma V, Rasi V, et al.: The association of C-reactive protein, serum amyloid A, and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 2001, 156:451-456.
51. Johnson BD, Kip KE, Marroquin OC, et al.: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women - The National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:726-732.
52. Pepe MS, Janes H, Longton G, et al.: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004, 159:882-890.
53. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634-635.
54. Greenland P, O'Malley PG: When is a new prediction marker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005, 165:2454-2456.
55. Wilson PW: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
56. Diverse Populations Collaborative Group: Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart 2002, 88:222-228.
57. Brotman DJ, Walker E, Lauer MS, O'Brien RG: In search of fewer independent risk factors. Arch Intern Med. 2005, 165:138-145.
58. Manolio T: Novel risk markers and clinical practice. N Engl J Med 2003, 349:1587-1589.
59. Ridker PM: Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999, 130:933-937.